View Cart  

Single Trial May Be Enough for ABOM Drugs: Final Guidance

A A
Sponsors of treatments for acute bacterial otitis media (ABOM), an inflammation of the middle ear, may be able to use a single clinical trial to support an application under some circumstances, according to a final FDA guidance.

To View This Article:

Login

Subscribe To Drug Industry Daily